518 related articles for article (PubMed ID: 11925123)
1. Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer.
Covens A; Carey M; Bryson P; Verma S; Fung Kee Fung M; Johnston M
Gynecol Oncol; 2002 Apr; 85(1):71-80. PubMed ID: 11925123
[TBL] [Abstract][Full Text] [Related]
2. A systematic overview of chemotherapy effects in ovarian cancer.
Högberg T; Glimelius B; Nygren P;
Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
[TBL] [Abstract][Full Text] [Related]
3. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline.
Chu Q; Vincent M; Logan D; Mackay JA; Evans WK;
Lung Cancer; 2005 Dec; 50(3):355-74. PubMed ID: 16139391
[TBL] [Abstract][Full Text] [Related]
4. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
5. Carboplatin versus cisplatin in ovarian cancer.
Alberts DS
Semin Oncol; 1995 Oct; 22(5 Suppl 12):88-90. PubMed ID: 7481869
[TBL] [Abstract][Full Text] [Related]
6. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.
Ozols RF; Bundy BN; Greer BE; Fowler JM; Clarke-Pearson D; Burger RA; Mannel RS; DeGeest K; Hartenbach EM; Baergen R;
J Clin Oncol; 2003 Sep; 21(17):3194-200. PubMed ID: 12860964
[TBL] [Abstract][Full Text] [Related]
7. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial.
International Collaborative Ovarian Neoplasm Group
Lancet; 2002 Aug; 360(9332):505-15. PubMed ID: 12241653
[TBL] [Abstract][Full Text] [Related]
8. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Warm M; Bauknecht T; Schröder W; Olbricht S; Nitz U; Jackisch C
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-44-S15-52. PubMed ID: 9346222
[TBL] [Abstract][Full Text] [Related]
9. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients.
Holloway RW; Mehta RS; Finkler NJ; Li KT; McLaren CE; Parker RJ; Fruehauf JP
Gynecol Oncol; 2002 Oct; 87(1):8-16. PubMed ID: 12468336
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
Thigpen T; Vance R; Puneky L; Khansur T
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
Skarlos DV; Aravantinos G; Kosmidis P; Athanassiadis A; Stathopoulos GP; Pavlidis N; Bafaloukos D; Karphathios S; Papakostas P; Bamia C; Fountzilas G
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224
[TBL] [Abstract][Full Text] [Related]
12. The integration of paclitaxel and new platinum compounds in the treatment of advanced ovarian cancer.
Vermorken JB
Int J Gynecol Cancer; 2001; 11 Suppl 1():21-30. PubMed ID: 11488999
[TBL] [Abstract][Full Text] [Related]
13. Current status of chemotherapy for ovarian cancer.
Ozols RF
Semin Oncol; 1995 Oct; 22(5 Suppl 12):61-6. PubMed ID: 7481863
[TBL] [Abstract][Full Text] [Related]
14. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
15. Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis.
Bristow RE; Santillan A; Salani R; Diaz-Montes TP; Giuntoli RL; Meisner BC; Armstrong DK; Frick KD
Gynecol Oncol; 2007 Sep; 106(3):476-81. PubMed ID: 17688927
[TBL] [Abstract][Full Text] [Related]
16. Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel.
Ozols RF; Bookman MA; du Bois A; Pfisterer J; Reuss A; Young RC
Gynecol Oncol; 2006 Oct; 103(1):1-6. PubMed ID: 16904166
[No Abstract] [Full Text] [Related]
17. [Clinical study of topotecan and cisplatin as first line chemotherapy in epithelial ovarian cancer].
Meng LH; Kong BH; Zhang YZ; Yang XS; Wang LJ; Su SL; Jiang J; Cui BX; Wang B
Zhonghua Fu Chan Ke Za Zhi; 2007 Oct; 42(10):683-7. PubMed ID: 18241544
[TBL] [Abstract][Full Text] [Related]
18. Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
Armstrong DK; Bundy B; Wenzel L; Huang HQ; Baergen R; Lele S; Copeland LJ; Walker JL; Burger RA;
N Engl J Med; 2006 Jan; 354(1):34-43. PubMed ID: 16394300
[TBL] [Abstract][Full Text] [Related]
19. Intraperitoneal carboplatin-based chemotherapy for epithelial ovarian cancer.
Fujiwara K; Markman M; Morgan M; Coleman RL
Gynecol Oncol; 2005 Apr; 97(1):10-5. PubMed ID: 15790431
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute.
Hainsworth JD; Thompson DS; Bismayer JA; Gian VG; Merritt WM; Whorf RC; Finney LH; Dudley BS
Cancer Med; 2015 May; 4(5):673-81. PubMed ID: 25556916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]